Principal owner of Diamyd Medical transfers subscription rights to endowment insurance
Diamyd Medical (Nasdaq Stockholm First North, Ticker: DMYD B) announed today that its principal owner, and also the CEO of the Company, Anders Essen-Möller, who will subscribe for his full share of the Company’s ongoing share issue corresponding to approximately 21 percent or MSEK 4.6 of the total share issue of MSEK 22.1, has transferred 3,613,455 of his Series B subscription rights in Diamyd Medical to an endowment insurance. Accordingly, the corresponding new Series B shares, 1,204,485, will be held in an endowment insurance.
“There are certain tax advantages to holding securities in an endowment insurance,” says Anders Essen-Möller.
About Diamyd Medical
Diamyd Medical is dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell and medical technology.
Diamyd Medical develops the diabetes vaccine Diamyd®, an Antigen Based Therapy (ABT) based on the exclusively licensed GAD-molecule. The Company’s licensed technologies for GABA and Gliadin have also potential to become key pieces of the puzzle of a future solution to prevent, treat or cure autoimmune diabetes, and also certain inflammatory diseases. At this time six clinical studies are ongoing with Diamyd®. Diamyd Medical is with its holdings of 39% one of the major shareholders in the stem cell company Cellaviva AB. Stem cells can be expected to be used in Personalized Regenerative Medicine (PRM), for example for restoration of beta cell mass in diabetes patients where the autoimmune component of the disease has been arrested. Diamyd Medical also has holdings in the medtech company Companion Medical, Inc., San Diego, USA and in the gene therapy company Periphagen, Inc., Pittsburgh, USA.
Diamyd Medical’s B-share is traded on Nasdaq Stockholm First North under the ticker DMYD B. Remium Nordic AB is the Company’s Certified Adviser.
For further information, please contact:
Anders Essen-Möller, President and CEO
Phone: +46 70 55 10 679. E-mail: anders.essen-moller@diamyd.com
Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797. Website: www.diamyd.com.
Tags: